New immune booster takes on Hard-to-Treat cancers
NCT ID NCT05597839
First seen Nov 01, 2025 · Last updated Jun 23, 2026 · Updated 35 times
Summary
This study tested a new drug, DF9001, that helps the body's natural killer cells attack cancer cells. It was given alone or with another immunotherapy (Keytruda) to 24 adults with advanced solid tumors. The main goal was to check safety and find the best dose, with early signs of tumor response also measured.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SOLID TUMOR, ADULT are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
AMR Kansas City
Kansas City, Missouri, 64114, United States
-
Banner MD Anderson
Gilbert, Arizona, 85234, United States
-
Fox Chase Cancer Center
Philadelphia, Pennsylvania, 19111, United States
-
Icahn School of Medicine at Mount Sinai
New York, New York, 10029, United States
-
Mayo Clinic Arizona
Phoenix, Arizona, 85054, United States
-
Mayo Clinic Jacksonville
Jacksonville, Florida, 32224, United States
-
Mayo Clinic Minnesota
Rochester, Minnesota, 55905, United States
-
Medical University of South Carolina
Charleston, South Carolina, 29425, United States
-
Rhode Island Hospital
Providence, Rhode Island, 02903, United States
-
Rutgers
New Brunswick, New Jersey, 08903, United States
-
UC Irvine Medical Center
Irvine, California, 92617, United States
-
UMPC Hillman Cancer Center
Pittsburgh, Pennsylvania, 15232, United States
-
USC/Norris Comprehensive Cancer Center
Los Angeles, California, 90033, United States
-
University of Cincinnati
Cincinnati, Ohio, 45219, United States
-
University of Louisville Hospital
Louisville, Kentucky, 40202, United States
-
University of Wisconsin
Madison, Wisconsin, 53792, United States
-
Virginia Cancer Specialists
Fairfax, Virginia, 22031, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
DF9001 (an immunotherapy that targets natural killer cells) and pembrolizumab (Keytruda, an anti-PD-1 immunotherapy)
What this could lead to
If successful, this could point toward a new treatment option for advanced solid tumors that are hard to treat.
What could go wrong
This is an early, small study (24 people) focused on safety, so it may not show strong tumor shrinkage. Side effects from immune activation are possible.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.